| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
1 Program in Epidemiology, Fred Hutchinson Cancer Research Center; and Departments of 2 Epidemiology and 3 Medicine, University of Washington, Seattle, Washington
Requests for reprints: Noel S. Weiss, University of Washington, Box 357236, Seattle, WA 98195. Phone: 206-685-1788; Fax: 206-543-8525. E-mail: nweiss{at}u.washington.edu
We conducted a nested case-control study within a cohort of elderly Americans to examine the role of the insulin-like growth factor (IGF) signaling pathway in prostate cancer etiology. The distribution of genotypes of IGF-I (CA)n, IGF binding protein-3 (IGFBP-3) A-202C, and of the 2-bp deletion and (AGG)n polymorphisms in IGF-I receptor (IGF-IR) was compared between men with prostate cancer (n = 213) and equal number of controls matched on year of blood draw, survival until the date of diagnosis, race, and age. Among controls, the number of CA repeats in IGF-I was not correlated to any appreciable degree with plasma IGF-I concentration, whereas the IGFBP-3 CC genotype was associated with a relatively low level of plasma IGFBP-3. There was no association between prostate cancer risk and the number of CA repeats in IGF-I, IGFBP-3 genotype, or the presence of the 2-bp deletion in IGF-IR. There was a small increased risk among men who did not carry two copies of the (AGG)7 allele of IGF-IR. These results add to the evidence that the number of IGF-I CA repeats is not associated with prostate cancer risk. Our observation that men who do not carry two copies of the IGF-IR (AGG)7 allele are at increased risk of prostate cancer merits further investigation. (Cancer Epidemiol Biomarkers Prev 2006;15(12):2461–6)
This article has been cited by other articles:
|
|
 |
|
  S. Lonn, N. Rothman, W. R. Shapiro, H. A. Fine, R. G. Selker, P. M. Black, J. S. Loeffler, A. A. Hutchinson, and P. D. Inskip Genetic variation in insulin-like growth factors and brain tumor risk Neuro-oncol, August 1, 2008; 10(4): 553 - 559. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 W. Hernandez, C. Grenade, E. R. Santos, C. Bonilla, C. Ahaghotu, and R. A. Kittles IGF-1 and IGFBP-3 gene variants influence on serum levels and prostate cancer risk in African-Americans Carcinogenesis, October 1, 2007; 28(10): 2154 - 2159. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. Haluska, H. M. Shaw, G. N. Batzel, D. Yin, J. R. Molina, L. R. Molife, T. A. Yap, M. L. Roberts, A. Sharma, A. Gualberto, et al. Phase I Dose Escalation Study of the Anti Insulin-Like Growth Factor-I Receptor Monoclonal Antibody CP-751,871 in Patients with Refractory Solid Tumors Clin. Cancer Res., October 1, 2007; 13(19): 5834 - 5840. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 I. Cheng, K. DeLellis Henderson, C. A. Haiman, L. N. Kolonel, B. E. Henderson, M. L. Freedman, and L. Le Marchand Genetic Determinants of Circulating Insulin-Like Growth Factor (IGF)-I, IGF Binding Protein (BP)-1, and IGFBP-3 Levels in a Multiethnic Population J. Clin. Endocrinol. Metab., September 1, 2007; 92(9): 3660 - 3666. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Lonn, P. D. Inskip, M. N. Pollak, S. J. Weinstein, J. Virtamo, and D. Albanes Glioma Risk in Relation to Serum Levels of Insulin-Like Growth Factors Cancer Epidemiol. Biomarkers Prev., April 1, 2007; 16(4): 844 - 846. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Meeting Abstracts Online |
